US FDA approves Novartis Kesimpta (ofatumumab) for relapsing forms of MS treatment
Ofatumumab was first approved by the FDA in 2009 for the treatment of chronic lymphocytic leukaemia (CLL)
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.